Back to search results

EMERGENT TEEN: KarXT for Schizophrenia in Adolescents

This study is looking at how well and how safely KarXT works for teenagers with schizophrenia. Schizophrenia is a brain disorder that affects how a person thinks, feels, and behaves. You might be able to join if you are 13 to 17 years old and have been diagnosed with schizophrenia based on specific criteria. The study will compare KarXT to a placebo (an inactive substance that looks like the study drug). Researchers will measure changes in your symptoms using a tool called the Positive and Negative Syndrome Scale (PANSS) after 5 weeks. The study plans to enroll 166 participants, but its current status is unclear.

Study design
This is an interventional study comparing KarXT to a placebo. It plans to include 166 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measure of success is taken at Week 5.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07288567

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

Recruiting
PHASE3Ages 13–17InterventionalTreatment
Bristol-Myers Squibb
~166 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:KarXTKarXT Matching Placebo

At a glance

Recruiting sites
15 of 39 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
Measured over Week 5

Conditions

Schizophrenia

Explore related trials

Schizophrenia

Where it's being run

39 sites across 21 states
Romania6
California4
Texas4
Georgia3
Florida2
Illinois2
Massachusetts2
Colombia2

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of schizophrenia as defined by the The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,Text Revision (DSM-5-TR) criteria, confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL) and experiencing symptoms of psychosis at screening (Visit 1).
PANSS total score of at least 70 at screening (Visit 1) and randomization (Visit 2).
Participant has a CGI-S score of ≥ 4 at screening (Visit 1) and randomization (Visit 2).

Exclusion

Any primary DSM-5-TR disorder other than schizophrenia within 12 months before screening.
History or presence of clinically significant cardiovascular, pulmonary, hepatic impairment, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
All grades of hepatic impairment (mild \[Child-Pugh Class A\], moderate \[Child-Pugh Class B\], and severe \[Child-Pugh Class C\]). Participants with known intellectual disability defined as an IQ less than 70; or, either clinical evidence or known social or school history indicative of intellectual disability.
Any neurological disorder, except for Tourette's Syndrome.
Participants who have either a systolic blood pressure (sBP) or diastolic blood pressure (dBP) meeting criteria for stage 2 HTN, regardless of the presence or absence of symptoms.

What this trial measures

  • Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total ScoreWeek 5